Sign In
Buy MRK
$113.87
-1.62 (-1.40%)
At Close: Jun 18, 2026
Merck & Co., Inc. (MRK) Q2 2024 Earnings Call Transcript
02:41pm, Tuesday, 30'th Jul 2024
Merck & Co., Inc. (NYSE:MRK ) Q2 2024 Earnings Conference Call July 30, 2024 9:00 AM ET Company Participants Peter Dannenbaum - SVP, IR Rob Davis - Chairman and CEO Caroline Litchfield - CFO Dean Li -
Chart of the Day: Merck
01:14pm, Tuesday, 30'th Jul 2024
Merck is down 10% today. The Investment Committee discuss the biotech sector.
Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS View
12:25pm, Tuesday, 30'th Jul 2024
Merck (MRK) posts better than expected second-quarter results, backed by strong demand for blockbuster cancer drug Keytruda. The stock falls in pre-market trading, likely due to the EPS guidance slash
Merck Stock Slides on Lowered Adjusted EPS Guidance
12:21pm, Tuesday, 30'th Jul 2024
Shares of Merck & Co. (MRK) tumbled Tuesday after the pharmaceutical giant cut its full-year adjusted profit guidance.
Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
10:55am, Tuesday, 30'th Jul 2024
Merck & Co. Inc. NYSE: MRK delivered a solid earnings report before the market opened on July 30, 2024. However, the stock was down over 4% in early trading after the company cut its full-year earning
Compared to Estimates, Merck (MRK) Q2 Earnings: A Look at Key Metrics
10:36am, Tuesday, 30'th Jul 2024
While the top- and bottom-line numbers for Merck (MRK) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wa
Options Traders Blast 2 Pharma Socks After Earnings
10:12am, Tuesday, 30'th Jul 2024
Pharmaceutical giants Merck & Co Inc (NYSE:MRK) and Pfizer Inc (NYSE:PFE) today reported second-quarter results.
Merck (MRK) Q2 Earnings and Revenues Top Estimates
08:41am, Tuesday, 30'th Jul 2024
Merck (MRK) came out with quarterly earnings of $2.28 per share, beating the Zacks Consensus Estimate of $2.16 per share. This compares to loss of $2.06 per share a year ago.
Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda
08:04am, Tuesday, 30'th Jul 2024
CNBC's Joe Kernen reports on the company's quarterly earnings results.
Merck beats profit and sales expectations amid Keytruda strength, but provides mixed full-year outlook
06:45am, Tuesday, 30'th Jul 2024
Shares of Merck & Co. MRK, +2.01% slipped 0.6% in premarket trading Tuesday, after the drug maker reported second-quarter profit and sales that beat expectations, amid strength in sales of cancer trea
Merck second quarter tops Street view on strong Keytruda sales
06:32am, Tuesday, 30'th Jul 2024
Merck & Co posted higher-than-expected second-quarter results on Tuesday on strong growth of its blockbuster cancer immunotherapy Keytruda, the world's best-selling prescription medicine.
Merck beats earnings expectations, raises sales outlook on strong demand for top drugs like Keytruda
06:31am, Tuesday, 30'th Jul 2024
Merck reported second-quarter revenue and adjusted earnings that topped estimates as it saw strong sales from its blockbuster cancer drug Keytruda as well as other treatments in its oncology and vacci
Merck Announces Second-Quarter 2024 Financial Results
06:30am, Tuesday, 30'th Jul 2024
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Second-Quarter 2024 Financial Results.
Pfizer And Merck's Earnings Previews: Uncorrelated To Big Tech, And Growth Styles
06:58am, Monday, 29'th Jul 2024
Both Merck and Pfizer are expected to report their Q2 '24 financial results on Tuesday morning, July 30 '24, before the opening bell. It's time for Pfizer to make hay after the pandemic spike, when th
Germany's Merck raises 2024 sales forecast
01:05pm, Friday, 26'th Jul 2024
Germany's Merck on Friday further its forecast for the group and said it now expects net sales to be between 20.7 billion euros ($22.49 billion) and 22.1 billion euros for 2024.
